Chemotherapy
Curcumin impacts on cisplatin sensitivity determining apoptotic boost in mesothelioma
Biomedicine & Pharmacotherapy 2025 December [Link] Miriam Piccioni, Emilia Caputo, Rossana Cuciniello, Francesco Di Meo, Anna Valentino, Gianluigi Petillo, Elena Rinaldi, Orsolina Petillo, Alfonso Baldi, Stefania Filosa, Paolo Bergamo, Stefania Crispi Abstract Cancer is one of the main diseases causing one-third of the worldwide death every year. The recent progresses achieved in chemotherapy have increased…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 January 9 [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition…
Read MorePembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
The Lancet. Oncology 2025 December [Link] Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer Abstract Background: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in…
Read MoreA novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing
Scientific Reports 2025 November 21 [Link] Yang Liu, Yang Yang, Songlin An, Hua Wan, Minghao Zhang, Ruihong Yin, Weiting Zhao, Li Huang, Yunshan Zhao, Chenggang Li Abstract Malignant mesothelioma (MM) is a rare, aggressive cancer with poor outcomes due to its heterogeneity and therapy resistance. Patient-derived organoids (PDOs) have emerged as a promising tool for…
Read MoreHyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases
Oncology 2025 November 20 [Link] Yu-An Zheng, Ke-Cheng Chen, Pei-Ming Huang, Mong-Wei Lin, Shuenn-Wen Kuo, Jang-Ming Lee Abstract Introduction: Hyperthermic intrathoracic chemotherapy (HITHOC) is an intraoperative treatment that involves the perfusion of heated chemotherapy agents within the thoracic cavity. Photodynamic therapy (PDT) utilizes systemically administered photosensitizing agents and targeted light exposure to eliminate residual cancer…
Read MoreUnraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Management
Cureus 2025 October 15 [Link] Othmane Zouiten, Latifa Azarou, Hasnaa Hadiri, Hanane Rais, Rhizlane Belbaraka Abstract Peritoneal mesothelioma is a rare and aggressive tumor, and its management remains poorly standardized in the literature. This case highlights the diagnostic and therapeutic challenges through a 56-year-old woman with no significant medical history or known asbestos exposure, who…
Read MoreComprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma
Clinical and Experimental Medicine 2025 November 18 [Link] Jun Li, Hongye He, Yutao Zhang, Muhammad Salman Azhar, Yongxiang Wang Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive thoracic malignancy primarily linked to asbestos exposure. Despite advances in research, the prognosis of MPM remains poor, and there is a lack of efficient and precise…
Read MoreNeoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review
Translational Lung Cancer Research 2025 October 31 [Link] Illaa Smesseim, Jo Raskin, Jacobus A Burgers Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The role of surgery in its management remains controversial, with ongoing debate regarding the definition of resectable disease. Neoadjuvant therapy aims to reduce tumor burden. This systematic review…
Read MoreUse of Patient-Derived Organoids for Pleural Mesothelioma 3D modelling
American Journal of Physiology Lung Cellular and Molecular Physiology 2025 October 29 [Link] Luca Volpini, Federica Monaco, Elisabetta Casalone, Elton Jalis Herman, Rebecca Filomena, Sandra Manzotti, Olga Strogovets, Gianluca Moroncini, Matteo Mozzicafreddo, Antonella Poloni, Elena Marinelli Busilacchi, Francesca Gonnelli, Francesca Barbisan, Gaia Goteri, Lina Zuccatosta, Martina Bonifazi, Giuseppe Matullo, Jiri Neuzil, Lory Santarelli, Najib M…
Read MoreDual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression
Cells 2025 October 15 [Link] Luca Hegedüs, Silvia Qaisieh, Christian Stülpnagel, Yavar Ganjeh Khor Dezfouli, Winny Tambo, Fabian Doerr, Natalie Baldes, Dirk Theegarten, Martin Schuler, Servet Bölükbas, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare cancer that often develops after a decades-long latency period and confers a grim prognosis. Novel, biomarker-based therapeutic modalities…
Read More
Skip to content